The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis
| Autor: | Yuzhen Liang, Yunhua Liao, Zichun Huang, Ning Xia, Manqiu Mo |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
Population Cochrane Library Gastroenterology Non-alcoholic Fatty Liver Disease Internal medicine Diabetes mellitus Humans Medicine Adverse effect education Sodium-Glucose Transporter 2 Inhibitors education.field_of_study Symporters Hepatology business.industry Sodium Fatty liver medicine.disease Fibrosis Glucose Diabetes Mellitus Type 2 Meta-analysis Relative risk business Body mass index |
| Zdroj: | Digestive and Liver Disease. 54:461-468 |
| ISSN: | 1590-8658 |
| Popis: | BACKGROUND In recent years, sodium-glucose co-transporter 2 inhibitors (SGLT2is) have been increasingly used in the treatment of patients with non-alcoholic fatty liver disease (NAFLD). This updated meta-analysis aimed to evaluate the efficacy and safety of SGLT2is for patients with NAFLD. METHODS PubMed, Embase, Cochrane Library, Web of Science, Wan Fang, China National Knowledge Infrastructure and VIP databases were searched for relevant studies from inception to April 30, 2021. Values of weighted mean differences (WMDs) and risk ratios (RRs) were determined for continuous and dichotomous outcomes, respectively. RESULTS A total of 1,498 patients with NAFLD from 20 studies were included for further analysis. Pooled analyses indicated significant improvements in body mass index [WMD: -0.84 kg/m2, 95% CI (-1.09, -0.60)], alanine aminotransferase [WMD: -4.36 U/L, 95% CI (-7.17, -1.54)], aspartate aminotransferase [WMD: -2.94 U/L, 95% CI (-5.33, -0.55)], fasting plasma glucose [WMD: -4.08 mmol/L, 95% CI (-6.21, -1.95)] and fibrosis-4 index [WMD: -0.08, 95% CI (-0.11, -0.05)] following SGLT2i treatment (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect